The survival of multiple myeloma (MM) patients has markedly improved over the last two decades because of introduction of several novel classes of anti-MM drugs including immunomodulatory drugs (IMiDs; thalidomide, lenalidomide and pomalidomide), proteasome inhibitors (bortezomib, ixazomib, and carfilzomib), and naked antibodies (anti-CD38 antibodies [daratumumab and isatuximab] and SLAM family member 7 (SLAMF7)-targeting antibodies [elotuzumab]) [1]. This evidence concerns the gene SLAMF7 and plasma cell myeloma.